DE10248141B4 - Nukleinsäuren und deren Verwendung für die Gentherapie - Google Patents
Nukleinsäuren und deren Verwendung für die Gentherapie Download PDFInfo
- Publication number
- DE10248141B4 DE10248141B4 DE10248141A DE10248141A DE10248141B4 DE 10248141 B4 DE10248141 B4 DE 10248141B4 DE 10248141 A DE10248141 A DE 10248141A DE 10248141 A DE10248141 A DE 10248141A DE 10248141 B4 DE10248141 B4 DE 10248141B4
- Authority
- DE
- Germany
- Prior art keywords
- vector
- sequence
- tumor
- vectors
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 38
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 33
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 33
- 238000001415 gene therapy Methods 0.000 title description 15
- 239000013598 vector Substances 0.000 claims abstract description 86
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 49
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 45
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 44
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 28
- 108010082808 4-1BB Ligand Proteins 0.000 claims abstract description 25
- 102000002627 4-1BB Ligand Human genes 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims description 66
- 241000700605 Viruses Species 0.000 claims description 43
- 239000002245 particle Substances 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 19
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 18
- 230000003308 immunostimulating effect Effects 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 description 24
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 238000002595 magnetic resonance imaging Methods 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 11
- 238000009169 immunotherapy Methods 0.000 description 11
- 241000701022 Cytomegalovirus Species 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101100406366 Caenorhabditis elegans pad-2 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101150108558 PAD1 gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10248141A DE10248141B4 (de) | 2002-10-11 | 2002-10-11 | Nukleinsäuren und deren Verwendung für die Gentherapie |
| PT37579513T PT1556411E (pt) | 2002-10-11 | 2003-10-10 | Vetores adenovirais que expressam interleucina-12 de cadeia única e ligando 4-1bb |
| ES03757951.3T ES2440951T3 (es) | 2002-10-11 | 2003-10-10 | Vectores adenovirales que expresan la interleucina-12 de cadena sencilla y el ligando 4-1BB |
| JP2004544141A JP4615311B2 (ja) | 2002-10-11 | 2003-10-10 | ウイルスベクターおよびその遺伝子治療のための使用 |
| DK03757951.3T DK1556411T3 (da) | 2002-10-11 | 2003-10-10 | Adenovirusvektorer som udtrykker enkeltkædet interleukin-12 og 4-1BB ligand |
| PCT/EP2003/011252 WO2004035799A2 (de) | 2002-10-11 | 2003-10-10 | Virale vektoren und deren verwendung für die gentherapie |
| EP03757951.3A EP1556411B1 (de) | 2002-10-11 | 2003-10-10 | Adenovirale Vektoren die Einzelketten Interleukin-12 und 4-1BB Ligand exprimieren |
| SI200332329T SI1556411T1 (sl) | 2002-10-11 | 2003-10-10 | Adenovirusni vektorji, ki eksprimirajo enojnoveriĹľni interlevkin-12 in 4-1BB ligand |
| AU2003273983A AU2003273983A1 (en) | 2002-10-11 | 2003-10-10 | Viral vectors and the use of the same for gene therapy |
| US10/530,706 US8067227B2 (en) | 2002-10-11 | 2003-10-10 | Viral vectors and the use of the same for gene therapy |
| JP2010192832A JP2011036251A (ja) | 2002-10-11 | 2010-08-30 | ウイルスベクターおよびその遺伝子治療のための使用 |
| CY20131101171T CY1114777T1 (el) | 2002-10-11 | 2013-12-27 | Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10248141A DE10248141B4 (de) | 2002-10-11 | 2002-10-11 | Nukleinsäuren und deren Verwendung für die Gentherapie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE10248141A1 DE10248141A1 (de) | 2004-09-02 |
| DE10248141B4 true DE10248141B4 (de) | 2007-04-19 |
Family
ID=32102775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10248141A Expired - Fee Related DE10248141B4 (de) | 2002-10-11 | 2002-10-11 | Nukleinsäuren und deren Verwendung für die Gentherapie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8067227B2 (enExample) |
| EP (1) | EP1556411B1 (enExample) |
| JP (2) | JP4615311B2 (enExample) |
| AU (1) | AU2003273983A1 (enExample) |
| CY (1) | CY1114777T1 (enExample) |
| DE (1) | DE10248141B4 (enExample) |
| DK (1) | DK1556411T3 (enExample) |
| ES (1) | ES2440951T3 (enExample) |
| PT (1) | PT1556411E (enExample) |
| SI (1) | SI1556411T1 (enExample) |
| WO (1) | WO2004035799A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004069272A2 (en) * | 2003-02-05 | 2004-08-19 | Movecare Ltd | Adjuvant combination for use in the immunization of a mamal comprising il2 and il12 |
| DE102005055128B4 (de) * | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| CN102174479B (zh) * | 2011-03-02 | 2013-04-03 | 北京锤特生物科技有限公司 | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| AU2012322999B2 (en) | 2011-10-11 | 2017-08-10 | Universitat Zurich Prorektorat Mnw | Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy |
| JP6912384B2 (ja) | 2015-04-22 | 2021-08-04 | キュアバック アーゲー | 癌疾患の処置のための、ｒｎａ含有組成物 |
| EP3390643B8 (en) * | 2015-12-18 | 2023-08-02 | OncoSec Medical Incorporated | Plasmid constructs for heterologous protein expression and methods of use |
| ES2718192T3 (es) | 2016-02-25 | 2019-06-28 | Provecs Medical Gmbh | Sistema vector inmunoestimulante novedoso |
| DK3458083T5 (da) | 2016-05-18 | 2024-10-21 | Modernatx Inc | Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf |
| CN110337305A (zh) | 2017-02-28 | 2019-10-15 | 赛诺菲 | 治疗性rna |
| AU2018261102B2 (en) * | 2017-05-02 | 2025-01-23 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
| US20220347244A1 (en) * | 2018-01-19 | 2022-11-03 | Kolon Life Science, Inc. | Recombinant vaccinia virus and pharmaceutical composition comprising same |
| US11230699B2 (en) * | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020018767A1 (en) * | 2000-07-27 | 2002-02-14 | See-Woo Lee | Anti-cancer cellular vaccine |
| WO2002027007A2 (en) * | 2000-09-25 | 2002-04-04 | Regents Of The University Of Michigan | Production of viral vectors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5573764A (en) * | 1994-01-21 | 1996-11-12 | Genetics Institute, Inc. | Use of interleukin-12 to prevent graft versus host disease |
| AU3209300A (en) | 1999-01-15 | 2000-08-01 | Mount Sinai School Of Medicine Of The City University Of New York, The | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines |
-
2002
- 2002-10-11 DE DE10248141A patent/DE10248141B4/de not_active Expired - Fee Related
-
2003
- 2003-10-10 US US10/530,706 patent/US8067227B2/en not_active Expired - Fee Related
- 2003-10-10 ES ES03757951.3T patent/ES2440951T3/es not_active Expired - Lifetime
- 2003-10-10 SI SI200332329T patent/SI1556411T1/sl unknown
- 2003-10-10 EP EP03757951.3A patent/EP1556411B1/de not_active Expired - Lifetime
- 2003-10-10 JP JP2004544141A patent/JP4615311B2/ja not_active Expired - Fee Related
- 2003-10-10 AU AU2003273983A patent/AU2003273983A1/en not_active Abandoned
- 2003-10-10 PT PT37579513T patent/PT1556411E/pt unknown
- 2003-10-10 WO PCT/EP2003/011252 patent/WO2004035799A2/de not_active Ceased
- 2003-10-10 DK DK03757951.3T patent/DK1556411T3/da active
-
2010
- 2010-08-30 JP JP2010192832A patent/JP2011036251A/ja active Pending
-
2013
- 2013-12-27 CY CY20131101171T patent/CY1114777T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020018767A1 (en) * | 2000-07-27 | 2002-02-14 | See-Woo Lee | Anti-cancer cellular vaccine |
| WO2002027007A2 (en) * | 2000-09-25 | 2002-04-04 | Regents Of The University Of Michigan | Production of viral vectors |
Non-Patent Citations (3)
| Title |
|---|
| MELERO i: et al. II-12 gene therapy for cancer: in synergy with other immunotherapies (2001) Trends in immunology Vol. 22(3), Seite 113-115 * |
| PubMed PMID 12202906 (Abstr. zu: Gillies, S.D. et al., Cancer Immunol. Immunother. 51(8), 2002, S. 449-60 * |
| Tan J.T. et al., J. Immunol. 163, 1999, S. 4859-68 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003273983A1 (en) | 2004-05-04 |
| WO2004035799A2 (de) | 2004-04-29 |
| JP2006511212A (ja) | 2006-04-06 |
| CY1114777T1 (el) | 2016-12-14 |
| ES2440951T3 (es) | 2014-01-31 |
| DE10248141A1 (de) | 2004-09-02 |
| US20060153805A1 (en) | 2006-07-13 |
| SI1556411T1 (sl) | 2014-01-31 |
| PT1556411E (pt) | 2014-01-07 |
| EP1556411A2 (de) | 2005-07-27 |
| JP4615311B2 (ja) | 2011-01-19 |
| US8067227B2 (en) | 2011-11-29 |
| WO2004035799A3 (de) | 2004-06-10 |
| JP2011036251A (ja) | 2011-02-24 |
| AU2003273983A8 (en) | 2004-05-04 |
| EP1556411B1 (de) | 2013-10-02 |
| DK1556411T3 (da) | 2014-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69230506T2 (de) | Lymphokine gentherapie bei krebs in kombination mit tumorantigenen | |
| DE69637480T2 (de) | Bioaktive il-12 fusionsproteine | |
| DE69836219T2 (de) | Verwendung von herpes-vektoren zur tumortherapie | |
| DE69435096T2 (de) | Zusammensetzung zur in vivo erzeugung von therapeutischen produkten | |
| DE69434781T2 (de) | Defektive rekombinante adenoviren zur tumor-gentherapie | |
| DE69735643T2 (de) | IL12 zur Gentherapie der Tumoren | |
| DE10248141B4 (de) | Nukleinsäuren und deren Verwendung für die Gentherapie | |
| DE60038503T2 (de) | AKTIVIERUNG DES IMMUNSYSTEMS DURCH EINEN ANTIGEN UND EINEN NF-kappaB AUSLÖSER | |
| DE69313443T2 (de) | Warte-effekt bei tumorzerstörender therapie | |
| DE69636863T2 (de) | Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren | |
| DE69834330T2 (de) | Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie | |
| DE69706593T2 (de) | Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier | |
| DE60309513T2 (de) | Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten | |
| DE69231250T2 (de) | Kombinierte zelluläre und immunsuppressive therapien | |
| EP2658566A1 (de) | Sirna gegen cbl-b und optional il2 und il12 zur verwendung in der behandlung von krebs | |
| DE69232890T2 (de) | Regulierung der systemischen immunantworten mittels zytokinen und antigenen | |
| KR100481230B1 (ko) | 이식에서 이식편 거부를 예방하고, 보편적인 유전자 치료 숙주세포를 생산하는 방법 | |
| WO1995023216A1 (de) | Verfahren zur herstellung von klonogenen fibroblasten, verfahren zur gentransfizierung von fibroblasten und so erhaltene gentransfizierte fibroblasten | |
| WO1996005866A2 (de) | Lebendvakzine zur behandlung von tumorerkrankungen | |
| CN105079792A (zh) | Il-17在提高间充质干细胞免疫抑制功能中的应用 | |
| DE60035049T2 (de) | Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung | |
| DE69534633T2 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| DE102005055128B4 (de) | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor | |
| DE69828414T2 (de) | Mukosale zytotoxische t-lymphozytenantwort | |
| DE69331574T2 (de) | Thymus-stammendes, immunverstärkendes agens zur therapeutischen verwendung in einem wirt mit einem angegriffenen immunsystem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8125 | Change of the main classification |
Ipc: C12N 15/861 AFI20051017BHDE |
|
| 8364 | No opposition during term of opposition | ||
| R082 | Change of representative |
Representative=s name: KEHL, ASCHERL, LIEBHOFF & ETTMAYR PATENTANWAEL, DE |
|
| R081 | Change of applicant/patentee |
Owner name: PROVECS MEDICAL GMBH, DE Free format text: FORMER OWNER: UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF (UKE), 20251 HAMBURG, DE |
|
| R082 | Change of representative |
Representative=s name: GRUENECKER PATENT- UND RECHTSANWAELTE PARTG MB, DE Representative=s name: KEHL, ASCHERL, LIEBHOFF & ETTMAYR PATENTANWAEL, DE Representative=s name: KEHL, ASCHERL, LIEBHOFF & ETTMAYR - PATENTANWA, DE |
|
| R082 | Change of representative |
Representative=s name: GRUENECKER PATENT- UND RECHTSANWAELTE PARTG MB, DE |
|
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |